Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN
$182.50
Closing Price on July 28, 2021
ALXN Articles
24/7 Wall St. has reviewed the top biotech companies, and the February 27 short interest data have been compared with the mid-February figures. Across the board, all the selected stocks have seen...
Published:
The short interest data are out for the February 13 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
Published:
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
Tuesday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls include GE, Gilead Sciences, Oracle, Under Armour and El Pollo Loco.
Published:
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or...
Published:
Last Updated:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published:
Short interest in biotech leaders changed from directional to stock specific in the first two weeks of October.
Published:
In a new report, Stifel analysts highlight their top biotech stocks with strong earnings momentum and possible catalysts to buy right now.
Published:
Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech analysts feels could be a very solid third-quarter earnings season.
Published:
The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most recent report.
Published:
For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams of revenue.
Published: